<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
  <channel>
    <title><![CDATA[ Personalized Diagnostics ]]></title>
    <description><![CDATA[Welcome to the Personalized Diagnostics Podcast.

We are going to be talking to some of the greatest minds and personalities in the diagnostics space – the engine which is driving personalized medicine forward.
We will be exploring the unmet need for better diagnostics across the patient journey  - from screening to treatment to treatment monitoring,  new assay development, technologies such as next generation sequencing  and artificial intelligence plus we’ll be  tackling  issues in reimbursement and health economics-  how we’re going to pay for all this and how diagnostics can provide value to the health care system.

Thanks for listening.  
]]></description>
    <link>http://thepdxpodcast.cast.rocks</link>
    <generator>Cast – https://tryca.st/</generator>
    <lastBuildDate>Mon, 13 Jul 2020 14:59:35 GMT</lastBuildDate>
    <pubDate>Wed, 04 Dec 2019 00:11:42 GMT</pubDate>
    <copyright><![CDATA[Copyright Joseph Anderson, MD]]></copyright>
    <language><![CDATA[en]]></language>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <itunes:author>Joseph Anderson, MD</itunes:author>
    <itunes:subtitle><![CDATA[Welcome to the Personalized Diagnostics Podcast.

We are going to be talking to some of the greatest minds and personalities in the diagnostics space – the engine which is driving personalized medicine forward.
We will be exploring the unmet need for ...]]></itunes:subtitle>
    <itunes:summary><![CDATA[Welcome to the Personalized Diagnostics Podcast.

We are going to be talking to some of the greatest minds and personalities in the diagnostics space – the engine which is driving personalized medicine forward.
We will be exploring the unmet need for better diagnostics across the patient journey  - from screening to treatment to treatment monitoring,  new assay development, technologies such as next generation sequencing  and artificial intelligence plus we’ll be  tackling  issues in reimbursement and health economics-  how we’re going to pay for all this and how diagnostics can provide value to the health care system.

Thanks for listening.  
]]></itunes:summary>
    <itunes:owner>
      <itunes:name>Joseph Anderson, MD</itunes:name>
      <itunes:email>joe@magpiedx.com</itunes:email>
    </itunes:owner>
    <itunes:explicit>clean</itunes:explicit>
    <itunes:image href="https://cast.rocks/hosting/21156/feeds/6MGG9.jpg?e=66f5d52"/>
    <itunes:category text="Health &amp; Fitness">
      <itunes:category text="Medicine"/>
    </itunes:category>
    <itunes:category text="Science">
      <itunes:category text="Life Sciences"/>
    </itunes:category>
    <itunes:category text="News">
      <itunes:category text="Tech News"/>
    </itunes:category>
    <item>
      <title><![CDATA[Jeffery Taubenberger, MD, PhD, of the NIH, Sequencing the 1918 Spanish Flu and What do we know About the Novel Coronavirus? - Episode 20]]></title>
      <description><![CDATA[What can we learn from previous pandemics to apply to the current situation? 

What do we actually know to be true about the novel coronavirus?

Jeffrey Taubenberger, MD, PhD, a physician-scientist and investigator at the National Institutes of Health, joins us to discuss his landmark work in sequencing the 1918 Spanish flu virus and to provide insights into the current novel coronavirus global pandemic.
]]></description>
      <guid isPermaLink="false">9W70RZWY-TM4PLDI</guid>
      <pubDate>Sun, 12 Jul 2020 22:42:42 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Dr-Jeffery-Taubenberger.mp3" length="25675339" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[What can we learn from previous pandemics to apply to the current situation? 

What do we actually know to be true about the novel coronavirus?

Jeffrey Taubenberger, MD, PhD, a physician-scientist and investigator at the National Institutes of Healt ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[What can we learn from previous pandemics to apply to the current situation? 

What do we actually know to be true about the novel coronavirus?

Jeffrey Taubenberger, MD, PhD, a physician-scientist and investigator at the National Institutes of Health, joins us to discuss his landmark work in sequencing the 1918 Spanish flu virus and to provide insights into the current novel coronavirus global pandemic.
]]></itunes:summary>
      <itunes:duration>0:31:59</itunes:duration>
      <itunes:length>25675339</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[BRUNO LARVOL, FOUNDER AND CEO OF LARVOL - PREVIEW 3]]></title>
      <description><![CDATA[Change can be slow - particularly in #healthcare.

Establishing clinical validity and clinical utility can be slow.

Getting regulatory approvals can be slow.

Gaining payor acceptance can be slow.]]></description>
      <guid isPermaLink="false">Q4QRVAE-DEBXU5WM</guid>
      <pubDate>Sun, 12 Jul 2020 22:31:35 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/bruno-prev-3.mp3" length="606418" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Change can be slow - particularly in #healthcare.

Establishing clinical validity and clinical utility can be slow.

Getting regulatory approvals can be slow.

Gaining payor acceptance can be slow.]]></itunes:subtitle>
      <itunes:summary><![CDATA[Change can be slow - particularly in #healthcare.

Establishing clinical validity and clinical utility can be slow.

Getting regulatory approvals can be slow.

Gaining payor acceptance can be slow.]]></itunes:summary>
      <itunes:duration>0:00:43</itunes:duration>
      <itunes:length>606418</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Bruno Larvol, Founder and CEO of Larvol - Preview 2]]></title>
      <description><![CDATA[Where are we in this megatrend of precision #medicine?]]></description>
      <guid isPermaLink="false">SXOCBRJ-ZW2BUIK9</guid>
      <pubDate>Sun, 12 Jul 2020 22:30:30 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/bruno-prev-2-.mp3" length="1755267" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Where are we in this megatrend of precision #medicine?]]></itunes:subtitle>
      <itunes:summary><![CDATA[Where are we in this megatrend of precision #medicine?]]></itunes:summary>
      <itunes:duration>0:02:10</itunes:duration>
      <itunes:length>1755267</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Bruno Larvol, Founder and CEO of Larvol - Preview 1]]></title>
      <description><![CDATA[Since the human genome has been sequenced, it has become clear that the technology to sequence has far outstripped our capabilities to accurately classify and interpret genetic variants.

It turns out that genetic variants are much more common than we ever suspected and many - in some cases most - variants are of uncertain significance.

But is the attempt to accurately classify Variants of Uncertain Significance (VUS) a losing strategy?]]></description>
      <guid isPermaLink="false">8US52GQL-SGIUDI</guid>
      <pubDate>Sun, 12 Jul 2020 22:29:41 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/bruno-prev-1-.mp3" length="1435991" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Since the human genome has been sequenced, it has become clear that the technology to sequence has far outstripped our capabilities to accurately classify and interpret genetic variants.

It turns out that genetic variants are much more common than w ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Since the human genome has been sequenced, it has become clear that the technology to sequence has far outstripped our capabilities to accurately classify and interpret genetic variants.

It turns out that genetic variants are much more common than we ever suspected and many - in some cases most - variants are of uncertain significance.

But is the attempt to accurately classify Variants of Uncertain Significance (VUS) a losing strategy?]]></itunes:summary>
      <itunes:duration>0:01:46</itunes:duration>
      <itunes:length>1435991</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Bruno Larvol, Founder and CEO of the Healthcare Data Company, Larvol - Episode 19]]></title>
      <description><![CDATA[We have seen tremendous advances in sequencing technology.   And the cost to sequence is going to zero,  according to Moore's Law.  More and more genes and gene sets are being correlated with clinical outcome and response to therapy.

Is bioinformatics intelligence the missing link to realizing the promise of precision medicine?

 Will a company emerge as the Google or Amazon of cancer informatics? 

Our guest is Bruno Larvol, of the eponymous healthcare data company, Larvol.
]]></description>
      <guid isPermaLink="false">3887B60O-GSEXW29</guid>
      <pubDate>Mon, 22 Jun 2020 19:17:21 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Untitled.mp3" length="28861987" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[We have seen tremendous advances in sequencing technology.   And the cost to sequence is going to zero,  according to Moore's Law.  More and more genes and gene sets are being correlated with clinical outcome and response to therapy.

Is bioinformati ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[We have seen tremendous advances in sequencing technology.   And the cost to sequence is going to zero,  according to Moore's Law.  More and more genes and gene sets are being correlated with clinical outcome and response to therapy.

Is bioinformatics intelligence the missing link to realizing the promise of precision medicine?

 Will a company emerge as the Google or Amazon of cancer informatics? 

Our guest is Bruno Larvol, of the eponymous healthcare data company, Larvol.
]]></itunes:summary>
      <itunes:duration>0:34:37</itunes:duration>
      <itunes:length>28861987</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[DANE DICKSON, MD, FOUNDER AND CEO OF TAPROOT HEALTH - Preview 3 ]]></title>
      <description><![CDATA["We have to evolve."

Establishing a "gold standard" for real world evidence will allow us to move beyond what we can learn from the 4% of patients enrolled in clinical trials and allow #innovation to flourish.]]></description>
      <guid isPermaLink="false">2KOBQMA-0O0MB1EM</guid>
      <pubDate>Mon, 22 Jun 2020 19:03:17 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/prev-3-dd.mp3" length="573806" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["We have to evolve."

Establishing a "gold standard" for real world evidence will allow us to move beyond what we can learn from the 4% of patients enrolled in clinical trials and allow #innovation to flourish.]]></itunes:subtitle>
      <itunes:summary><![CDATA["We have to evolve."

Establishing a "gold standard" for real world evidence will allow us to move beyond what we can learn from the 4% of patients enrolled in clinical trials and allow #innovation to flourish.]]></itunes:summary>
      <itunes:duration>0:01:04</itunes:duration>
      <itunes:length>573806</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[DANE DICKSON, MD, FOUNDER AND CEO OF TAPROOT HEALTH -Preview 2]]></title>
      <description><![CDATA[Fewer than 4% of oncology patients ever make it onto a clinical trial. And these 4% may not even reflect the real-world patient experience.

How can we use real world data in a rigorous and thoughtful way to come up with new standards of evidence to help move innovation forward?]]></description>
      <guid isPermaLink="false">HCFST24F-I9HPVI</guid>
      <pubDate>Mon, 22 Jun 2020 19:01:52 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/dd-prev-2.mp3" length="759554" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Fewer than 4% of oncology patients ever make it onto a clinical trial. And these 4% may not even reflect the real-world patient experience.

How can we use real world data in a rigorous and thoughtful way to come up with new standards of evidence to  ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Fewer than 4% of oncology patients ever make it onto a clinical trial. And these 4% may not even reflect the real-world patient experience.

How can we use real world data in a rigorous and thoughtful way to come up with new standards of evidence to help move innovation forward?]]></itunes:summary>
      <itunes:duration>0:01:25</itunes:duration>
      <itunes:length>759554</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[DANE DICKSON, MD, FOUNDER AND CEO OF TAPROOT HEALTH -Preview 1]]></title>
      <description><![CDATA[There’s no question that we are awash in promising new technologies with the potential to advance precision medicine.

But is the existing infrastructure adequate to bring innovation into patient care?

It's generally recognized that the highest levels of evidence are generated via the prospective randomized trial. These trials, however, are extremely costly and time-consuming and generate only a limited number of conclusions from a small subset of patients which may not be truly reflective of the real-world patient experience.

Will we be able to evolve and find new ways to generate high levels of evidence to move precision medicine forward?]]></description>
      <guid isPermaLink="false">E4YRYJ4L-G5VCXR</guid>
      <pubDate>Mon, 22 Jun 2020 18:57:25 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/dd-prev-1-.mp3" length="876079" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[There’s no question that we are awash in promising new technologies with the potential to advance precision medicine.

But is the existing infrastructure adequate to bring innovation into patient care?

It's generally recognized that the highest leve ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[There’s no question that we are awash in promising new technologies with the potential to advance precision medicine.

But is the existing infrastructure adequate to bring innovation into patient care?

It's generally recognized that the highest levels of evidence are generated via the prospective randomized trial. These trials, however, are extremely costly and time-consuming and generate only a limited number of conclusions from a small subset of patients which may not be truly reflective of the real-world patient experience.

Will we be able to evolve and find new ways to generate high levels of evidence to move precision medicine forward?]]></itunes:summary>
      <itunes:duration>0:01:38</itunes:duration>
      <itunes:length>876079</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[DAne Dickson, MD, founder and CEO of Taproot Health - Episode 18]]></title>
      <description><![CDATA[There’s no question that we are awash in promising new technologies with the potential to advance precision medicine.

But is the existing infrastructure adequate to bring innovation into patient care?
It's generally recognized that the highest levels of evidence are generated via the prospective randomized trial.   These trials, however, are extremely costly and time-consuming and generate only limited conclusions from a small subset of patients which may not be truly reflective of the real-world patient experience.

 Will we be able to evolve and find new ways to generate high levels of evidence to move precision medicine forward? 

Dane Dixon, MD,  of Taproot Health joins us in one of our most important episodes to date.
]]></description>
      <guid isPermaLink="false">7VG174Q4-J5G66R</guid>
      <pubDate>Sun, 07 Jun 2020 20:12:36 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/dane-dickson.mp3" length="21471283" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[There’s no question that we are awash in promising new technologies with the potential to advance precision medicine.

But is the existing infrastructure adequate to bring innovation into patient care?
It's generally recognized that the highest level ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[There’s no question that we are awash in promising new technologies with the potential to advance precision medicine.

But is the existing infrastructure adequate to bring innovation into patient care?
It's generally recognized that the highest levels of evidence are generated via the prospective randomized trial.   These trials, however, are extremely costly and time-consuming and generate only limited conclusions from a small subset of patients which may not be truly reflective of the real-world patient experience.

 Will we be able to evolve and find new ways to generate high levels of evidence to move precision medicine forward? 

Dane Dixon, MD,  of Taproot Health joins us in one of our most important episodes to date.
]]></itunes:summary>
      <itunes:duration>0:35:10</itunes:duration>
      <itunes:length>21471283</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - PREVIEW 4]]></title>
      <description><![CDATA[The diagnostics #industry is very fragmented, in terms of testing laboratories, test developers, and testing methodologies used.

Companion diagnostics testing for targeted therapies is still done by a variety of methodologies, including immunohistochemistry, FISH, RT-PCR, RNA expression analysis as well as next-generation sequencing, and others.

The advent of next-generation #sequencing, as many predicted, has not - as of yet - led to a more unified approach to testing. Why is this?]]></description>
      <guid isPermaLink="false">A2UAMI6Y-BQK6GVI</guid>
      <pubDate>Fri, 05 Jun 2020 20:39:02 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/tracy-prev-4-.mp3" length="971057" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[The diagnostics #industry is very fragmented, in terms of testing laboratories, test developers, and testing methodologies used.

Companion diagnostics testing for targeted therapies is still done by a variety of methodologies, including immunohistoc ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[The diagnostics #industry is very fragmented, in terms of testing laboratories, test developers, and testing methodologies used.

Companion diagnostics testing for targeted therapies is still done by a variety of methodologies, including immunohistochemistry, FISH, RT-PCR, RNA expression analysis as well as next-generation sequencing, and others.

The advent of next-generation #sequencing, as many predicted, has not - as of yet - led to a more unified approach to testing. Why is this?]]></itunes:summary>
      <itunes:duration>0:01:11</itunes:duration>
      <itunes:length>971057</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - PREVIEW 3]]></title>
      <description><![CDATA[With the advent of next generation sequencing, we've gained the ability to test for nearly any and all genomic alterations – many or most of which are benign or of uncertain significance.

And, believe it or not, we encounter many benign or uncertain alterations in tumor related genes.

Targeted therapies have historically been developed with a relatively small number of alterations in mind. For example, KRAS testing focused originally only on codon 12 and 13 mutations. While, 90% of deleterious EGFR alterations in lung #cancer are either chromosome 19 deletion or the L858R mutation.

Are we in danger of watering down the size of the effect in clinical trials for targeted therapies by trying to incorporate too many genomic alterations in their #design?]]></description>
      <guid isPermaLink="false">8DPLCSPL-6HCL3DI</guid>
      <pubDate>Fri, 05 Jun 2020 20:36:51 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/tracy-prev-3.mp3" length="772347" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[With the advent of next generation sequencing, we've gained the ability to test for nearly any and all genomic alterations – many or most of which are benign or of uncertain significance.

And, believe it or not, we encounter many benign or uncertain ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[With the advent of next generation sequencing, we've gained the ability to test for nearly any and all genomic alterations – many or most of which are benign or of uncertain significance.

And, believe it or not, we encounter many benign or uncertain alterations in tumor related genes.

Targeted therapies have historically been developed with a relatively small number of alterations in mind. For example, KRAS testing focused originally only on codon 12 and 13 mutations. While, 90% of deleterious EGFR alterations in lung #cancer are either chromosome 19 deletion or the L858R mutation.

Are we in danger of watering down the size of the effect in clinical trials for targeted therapies by trying to incorporate too many genomic alterations in their #design?]]></itunes:summary>
      <itunes:duration>0:00:56</itunes:duration>
      <itunes:length>772347</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - PREVIEW 2]]></title>
      <description><![CDATA[Will this be a golden #era for #diagnostics?

Are we moving away from a model based on high-value #therapeutics and towards one based more on high-value diagnostics?]]></description>
      <guid isPermaLink="false">17MR9RKV-7PJ02J4</guid>
      <pubDate>Fri, 05 Jun 2020 20:35:14 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/tracy-prev-2-.mp3" length="460924" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Will this be a golden #era for #diagnostics?

Are we moving away from a model based on high-value #therapeutics and towards one based more on high-value diagnostics?]]></itunes:subtitle>
      <itunes:summary><![CDATA[Will this be a golden #era for #diagnostics?

Are we moving away from a model based on high-value #therapeutics and towards one based more on high-value diagnostics?]]></itunes:summary>
      <itunes:duration>0:00:33</itunes:duration>
      <itunes:length>460924</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - Preview 1]]></title>
      <description><![CDATA[September 25, 1998 - trastuzumab, one of the first targeted therapies with a companion diagnostic, received #FDA approval in breast #cancer.

The commercially available IHC and FISH companion #diagnostics were not incorporated into the pivotal clinical trial. They had to be subsequently "developed" and validated by way of concordance studies (which were not stellar).

Does this still happen today? Have we begun to appreciate the importance of embedding companion diagnostics directly into clinical trials?]]></description>
      <guid isPermaLink="false">CXBSICLG-78K6GVI</guid>
      <pubDate>Fri, 05 Jun 2020 20:34:08 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/tracy-prev-1.mp3" length="405140" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[September 25, 1998 - trastuzumab, one of the first targeted therapies with a companion diagnostic, received #FDA approval in breast #cancer.

The commercially available IHC and FISH companion #diagnostics were not incorporated into the pivotal clinic ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[September 25, 1998 - trastuzumab, one of the first targeted therapies with a companion diagnostic, received #FDA approval in breast #cancer.

The commercially available IHC and FISH companion #diagnostics were not incorporated into the pivotal clinical trial. They had to be subsequently "developed" and validated by way of concordance studies (which were not stellar).

Does this still happen today? Have we begun to appreciate the importance of embedding companion diagnostics directly into clinical trials?]]></itunes:summary>
      <itunes:duration>0:00:30</itunes:duration>
      <itunes:length>405140</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Tracy George, MD -  Executive Director of clinical trials and pharmaDX at ARUP Laboratories  - Episode 17]]></title>
      <description><![CDATA[Over the past 20 years we've seen the development of approximately 40 indications for targeted therapies with a companion diagnostic. How can we continue to build on these successes and develop even more effective strategies for developing targeted therapies with companion diagnostics and incorporating diagnostics into clinical trials?

Our guest is Tracy George, MD, Professor of Pathology at the University of Utah and the Executive Director of clinical trials and pharma DX at ARUP Laboratories.  
]]></description>
      <guid isPermaLink="false">AE0VZF3M-TKPGB9</guid>
      <pubDate>Thu, 21 May 2020 02:01:17 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Tracy-George-ARUP.mp3" length="21380659" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Over the past 20 years we've seen the development of approximately 40 indications for targeted therapies with a companion diagnostic. How can we continue to build on these successes and develop even more effective strategies for developing targeted t ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Over the past 20 years we've seen the development of approximately 40 indications for targeted therapies with a companion diagnostic. How can we continue to build on these successes and develop even more effective strategies for developing targeted therapies with companion diagnostics and incorporating diagnostics into clinical trials?

Our guest is Tracy George, MD, Professor of Pathology at the University of Utah and the Executive Director of clinical trials and pharma DX at ARUP Laboratories.  
]]></itunes:summary>
      <itunes:duration>0:25:15</itunes:duration>
      <itunes:length>21380659</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[DR. TOM STUBBS, CO-FOUNDER AND CEO OF CHRONOMICS - PREVIEW 3]]></title>
      <description><![CDATA[We’ve all heard the term “epigenetics.” But what does it actually mean?

#Epigenetics is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself.

It is somewhat of a catch-all term and does not apply to any one type of change or any one methodology for measuring these changes.]]></description>
      <guid isPermaLink="false">6I2HPWT7-VXCG14I</guid>
      <pubDate>Thu, 21 May 2020 01:46:22 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/tom-stubbs-prev-3.mp3" length="223842" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[We’ve all heard the term “epigenetics.” But what does it actually mean?

#Epigenetics is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself.

It is somewhat of a catch-all ter ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[We’ve all heard the term “epigenetics.” But what does it actually mean?

#Epigenetics is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself.

It is somewhat of a catch-all term and does not apply to any one type of change or any one methodology for measuring these changes.]]></itunes:summary>
      <itunes:duration>0:00:21</itunes:duration>
      <itunes:length>223842</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[DR. TOM STUBBS, CO-FOUNDER AND CEO OF CHRONOMICS - PREVIEW 2]]></title>
      <description><![CDATA[There appears to be a clear association between age and underlying chronic conditions such as #diabetes and #hypertension and the severity of a #covid19 illness.

Can epigenetics inform us of our risk of acquiring acute or infectious illnesses such as Covid-19 and their severity?]]></description>
      <guid isPermaLink="false">4KAXY3YK-Y7OUSOR</guid>
      <pubDate>Thu, 21 May 2020 01:44:33 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/tom-stubbs-prev-2-.mp3" length="623016" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[There appears to be a clear association between age and underlying chronic conditions such as #diabetes and #hypertension and the severity of a #covid19 illness.

Can epigenetics inform us of our risk of acquiring acute or infectious illnesses such a ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[There appears to be a clear association between age and underlying chronic conditions such as #diabetes and #hypertension and the severity of a #covid19 illness.

Can epigenetics inform us of our risk of acquiring acute or infectious illnesses such as Covid-19 and their severity?]]></itunes:summary>
      <itunes:duration>0:01:00</itunes:duration>
      <itunes:length>623016</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Dr. Tom Stubbs, Co-Founder and CEO of Chronomics - Preview 1]]></title>
      <description><![CDATA[How do we age?]]></description>
      <guid isPermaLink="false">A8BMQI9I-VIMS4I</guid>
      <pubDate>Thu, 21 May 2020 01:42:46 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/tom-stubbs-prev-1.mp3" length="1320810" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[How do we age?]]></itunes:subtitle>
      <itunes:summary><![CDATA[How do we age?]]></itunes:summary>
      <itunes:duration>0:02:06</itunes:duration>
      <itunes:length>1320810</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Dr. Tom Stubbs, Co-founder and CEO of Chronomics - Episode 16]]></title>
      <description><![CDATA[We've all heard the term biological age.  But what does it mean exactly?  How is it measured? And is it possible to "turn back the hands of time?"

Does the key to health, wellness and longevity lie in epigenetics?

We are joined by Dr. Tom Stubbs, Co- founder and CEO of Chronomics]]></description>
      <guid isPermaLink="false">7O0FYLOD-PHF47VI</guid>
      <pubDate>Fri, 08 May 2020 19:13:17 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Chronomics-Dr-Tom-Stubbs.mp3" length="17507491" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[We've all heard the term biological age.  But what does it mean exactly?  How is it measured? And is it possible to "turn back the hands of time?"

Does the key to health, wellness and longevity lie in epigenetics?

We are joined by Dr. Tom Stubbs, C ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[We've all heard the term biological age.  But what does it mean exactly?  How is it measured? And is it possible to "turn back the hands of time?"

Does the key to health, wellness and longevity lie in epigenetics?

We are joined by Dr. Tom Stubbs, Co- founder and CEO of Chronomics]]></itunes:summary>
      <itunes:duration>0:25:57</itunes:duration>
      <itunes:length>17507491</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Hagenkord's Korner  - Preview 2 ]]></title>
      <description><![CDATA[Slow down - testing for SARS-CoV-2 is not as simple as it may seem.

“What I really want to know is: if this test result is positive, what are the chances that my patient actually has the condition.

“Sensitivity and specificity really have no utility in a practical everyday clinical setting.

“You really want to know the positive predictive value and the negative predictive value.”]]></description>
      <guid isPermaLink="false">UK5HLDP-1ZG58KT9</guid>
      <pubDate>Mon, 27 Apr 2020 06:12:15 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/hagenkors-korner-prev-2.mp3" length="1801871" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Slow down - testing for SARS-CoV-2 is not as simple as it may seem.

“What I really want to know is: if this test result is positive, what are the chances that my patient actually has the condition.

“Sensitivity and specificity really have no utilit ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Slow down - testing for SARS-CoV-2 is not as simple as it may seem.

“What I really want to know is: if this test result is positive, what are the chances that my patient actually has the condition.

“Sensitivity and specificity really have no utility in a practical everyday clinical setting.

“You really want to know the positive predictive value and the negative predictive value.”]]></itunes:summary>
      <itunes:duration>0:03:04</itunes:duration>
      <itunes:length>1801871</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Hagenkord's Korner  - preview 1]]></title>
      <description><![CDATA[Slow down - testing for SARS-CoV-2 is complicated.

Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.

She joins us for this first installment of "Hagenkord's Korner."]]></description>
      <guid isPermaLink="false">J7VP2A8J-9YSYVI</guid>
      <pubDate>Mon, 27 Apr 2020 06:11:06 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/hagenkords-corner-prev-1-.mp3" length="1099114" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Slow down - testing for SARS-CoV-2 is complicated.

Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.

She joins us for this first installment of " ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Slow down - testing for SARS-CoV-2 is complicated.

Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.

She joins us for this first installment of "Hagenkord's Korner."]]></itunes:summary>
      <itunes:duration>0:02:02</itunes:duration>
      <itunes:length>1099114</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[RONDELL GRAHAM, M.B.B.S., HEAD OF GASTROINTESTINAL AND LIVER PATHOLOGY AT THE MAYO CLINIC - PREVIEW 4]]></title>
      <description><![CDATA[Entrectinib and larotrectinib have been approved to treat tumors with fusions in the neurotrophic tropomyosin receptor kinase (NTRK) gene – irrespective of the tumor’s site of origin.

These drugs are the second and third agents, overall, to have a tissue-agnostic indication approved by the FDA.

The first was pembrolizumab, an immunotherapy agent, indicated for tumors with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors in 2017.

Have we finally reached the point where tumor biology has become a more important consideration than site of origin?]]></description>
      <guid isPermaLink="false">BNB27JJQ-X3FECDI</guid>
      <pubDate>Mon, 27 Apr 2020 06:09:41 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rondell-prev-4-.mp3" length="622309" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Entrectinib and larotrectinib have been approved to treat tumors with fusions in the neurotrophic tropomyosin receptor kinase (NTRK) gene – irrespective of the tumor’s site of origin.

These drugs are the second and third agents, overall, to have a t ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Entrectinib and larotrectinib have been approved to treat tumors with fusions in the neurotrophic tropomyosin receptor kinase (NTRK) gene – irrespective of the tumor’s site of origin.

These drugs are the second and third agents, overall, to have a tissue-agnostic indication approved by the FDA.

The first was pembrolizumab, an immunotherapy agent, indicated for tumors with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors in 2017.

Have we finally reached the point where tumor biology has become a more important consideration than site of origin?]]></itunes:summary>
      <itunes:duration>0:00:50</itunes:duration>
      <itunes:length>622309</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Rondell Graham, M.B.B.S., Head of Gastrointestinal and Liver Pathology at the Mayo Clinic - Preview 3]]></title>
      <description><![CDATA[Microsatellite instability testing in #colon #cancer has evolved considerably over the past several years. It began as a way to screen for Lynch #Syndrome, a heritable condition, which accounts for about 5% of colon cancers.

MSI subsequently has been shown to be a prognostic factor in colon cancer.

And in its most recent incarnation as a biomarker, it has been shown to be predictive for response to immunotherapy. Pembrolizumab has been approved for patients with microsatellite instability-high tumors.

Interestingly, or perhaps counter-intuitively, patients with microsatellite unstable tumors actually have a better prognosis. Why is this?]]></description>
      <guid isPermaLink="false">JPD73DZU-RN3IK9</guid>
      <pubDate>Mon, 27 Apr 2020 06:08:34 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rakesh-prev-3.mp3" length="842549" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Microsatellite instability testing in #colon #cancer has evolved considerably over the past several years. It began as a way to screen for Lynch #Syndrome, a heritable condition, which accounts for about 5% of colon cancers.

MSI subsequently has bee ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Microsatellite instability testing in #colon #cancer has evolved considerably over the past several years. It began as a way to screen for Lynch #Syndrome, a heritable condition, which accounts for about 5% of colon cancers.

MSI subsequently has been shown to be a prognostic factor in colon cancer.

And in its most recent incarnation as a biomarker, it has been shown to be predictive for response to immunotherapy. Pembrolizumab has been approved for patients with microsatellite instability-high tumors.

Interestingly, or perhaps counter-intuitively, patients with microsatellite unstable tumors actually have a better prognosis. Why is this?]]></itunes:summary>
      <itunes:duration>0:01:03</itunes:duration>
      <itunes:length>842549</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Rondell Graham, M.B.B.S., Head of Gastrointestinal and Liver Pathology at the Mayo Clinic - Preview 2]]></title>
      <description><![CDATA[Diagnostic Testing can be thought of as occurring in three phases:

1. Pre-analytic phase - everything leading up to the actual testing, including properly filling out a requisition, blood draw, specimen handling, gross examination and tissue fixation

2. Analytic phase - the actual testing itself, which is “flashy” and most people understand

3. Post-analytic phase - results interpretation, report generation, communication with the ordering physician and planning for future testing

If the pre-analytic phase is suboptimal, everything that follows may be unreliable or uninformative.

Colloquially, this is known as “Garbage in, garbage out.”
]]></description>
      <guid isPermaLink="false">J4B7EICS-JI3SOR</guid>
      <pubDate>Mon, 27 Apr 2020 05:59:58 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rondell-prev-2-.mp3" length="540402" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Diagnostic Testing can be thought of as occurring in three phases:

1. Pre-analytic phase - everything leading up to the actual testing, including properly filling out a requisition, blood draw, specimen handling, gross examination and tissue fixatio ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Diagnostic Testing can be thought of as occurring in three phases:

1. Pre-analytic phase - everything leading up to the actual testing, including properly filling out a requisition, blood draw, specimen handling, gross examination and tissue fixation

2. Analytic phase - the actual testing itself, which is “flashy” and most people understand

3. Post-analytic phase - results interpretation, report generation, communication with the ordering physician and planning for future testing

If the pre-analytic phase is suboptimal, everything that follows may be unreliable or uninformative.

Colloquially, this is known as “Garbage in, garbage out.”
]]></itunes:summary>
      <itunes:duration>0:00:43</itunes:duration>
      <itunes:length>540402</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Rondell Graham, M.B.B.S., Head of Gastrointestinal and Liver Pathology at the Mayo Clinic - Preview 1]]></title>
      <description><![CDATA[It is not often we have a major paradigm shift in medicine.

Albert Broders, MD, was a pathologist at the Mayo Clinic. Early in his career, he described tumor grading, showing for the first time that features in cancer specimens observed under the microscope could predict outcomes.

This discovery was a massive paradigm shift, that quickly begat tumor staging and eventually the whole predictive biomarker field.

Rondell Graham, Head of GI and Liver Pathology at the Mayo Clinic, joins us this week on The Personalized Diagnostics Podcast, where we discuss predictive and prognostic markers in colon cancer, molecular diagnostics, digital pathology, the future of targeted therapies and much more.]]></description>
      <guid isPermaLink="false">4TAFH3A6-0UANHFR</guid>
      <pubDate>Mon, 27 Apr 2020 05:58:42 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rondell-prev-1-.mp3" length="452119" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[It is not often we have a major paradigm shift in medicine.

Albert Broders, MD, was a pathologist at the Mayo Clinic. Early in his career, he described tumor grading, showing for the first time that features in cancer specimens observed under the mi ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[It is not often we have a major paradigm shift in medicine.

Albert Broders, MD, was a pathologist at the Mayo Clinic. Early in his career, he described tumor grading, showing for the first time that features in cancer specimens observed under the microscope could predict outcomes.

This discovery was a massive paradigm shift, that quickly begat tumor staging and eventually the whole predictive biomarker field.

Rondell Graham, Head of GI and Liver Pathology at the Mayo Clinic, joins us this week on The Personalized Diagnostics Podcast, where we discuss predictive and prognostic markers in colon cancer, molecular diagnostics, digital pathology, the future of targeted therapies and much more.]]></itunes:summary>
      <itunes:duration>0:00:36</itunes:duration>
      <itunes:length>452119</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Hagenkord's Korner - SARS COV2 Testing]]></title>
      <description><![CDATA[We are introducing a new feature: "Hagenkord's Korner."  

Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.

This week we will be discussing how we have been hearing relatively little from experts such as physicians, epidemiologists, virologists and statisticians during the current pandemic.

We will also be discussing the pitfalls of testing and test development for SARS-CoV-2.]]></description>
      <guid isPermaLink="false">FGF1YA3K-SY8PVI</guid>
      <pubDate>Fri, 24 Apr 2020 02:27:25 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Jill-Hagenkord-Coronavirs-testing.mp3" length="5352067" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[We are introducing a new feature: "Hagenkord's Korner."  

Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.

This week we will be discussing how w ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[We are introducing a new feature: "Hagenkord's Korner."  

Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.

This week we will be discussing how we have been hearing relatively little from experts such as physicians, epidemiologists, virologists and statisticians during the current pandemic.

We will also be discussing the pitfalls of testing and test development for SARS-CoV-2.]]></itunes:summary>
      <itunes:duration>0:08:56</itunes:duration>
      <itunes:length>5352067</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Rondell Graham, M.B.B.S., Head of GI and Liver Pathology at the Mayo Clinic, Predictive and Prognostic Factors in Colon Cancer  - episode 15]]></title>
      <description><![CDATA[2020 marks the one hundredth anniversary of the publication of Albert Broder’s landmark paper on tumor grading.  

The foundation of what is now called personalized medicine is the idea that not all tumors or all patients are the same.   Differences in gene expression and phenotype correlate with outcome and inform how a patient is best treated.

Dr. Rondell Graham is head of gastrointestinal and liver pathology at the Mayo Clinic.   He joins us to discuss predictive and prognostic markers in colon cancer - where we've been, the implications of new technologies such as artificial intelligence, as well as the future of targeted therapies.
]]></description>
      <guid isPermaLink="false">EI8MXRL4-5Y7GB9</guid>
      <pubDate>Sat, 18 Apr 2020 17:05:20 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Rondell-Graham.mp3" length="22889899" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[2020 marks the one hundredth anniversary of the publication of Albert Broder’s landmark paper on tumor grading.  

The foundation of what is now called personalized medicine is the idea that not all tumors or all patients are the same.   Differences  ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[2020 marks the one hundredth anniversary of the publication of Albert Broder’s landmark paper on tumor grading.  

The foundation of what is now called personalized medicine is the idea that not all tumors or all patients are the same.   Differences in gene expression and phenotype correlate with outcome and inform how a patient is best treated.

Dr. Rondell Graham is head of gastrointestinal and liver pathology at the Mayo Clinic.   He joins us to discuss predictive and prognostic markers in colon cancer - where we've been, the implications of new technologies such as artificial intelligence, as well as the future of targeted therapies.
]]></itunes:summary>
      <itunes:duration>0:30:07</itunes:duration>
      <itunes:length>22889899</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[KRISTINE ASHCRAFT, CEO OF YOUSCRIPT - Preview 4]]></title>
      <description><![CDATA[Pharmacogenetics is the study of how people respond differently to drug therapy based on their unique genetic makeup.  Genetic variations cause differences in the expression of various enzymes involved in drug metabolism.

Health #economic studies have shown that the use of pharmacogenetic testing in clinical practice results in better outcomes  - by a variety of metrics.

Are payors interested in these data?  Of course they are.  Better outcomes generally save money as well.  
]]></description>
      <guid isPermaLink="false">3SL4Y9P5-LTEDN29</guid>
      <pubDate>Sat, 18 Apr 2020 03:22:08 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/kristine-prev-4.mp3" length="924322" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Pharmacogenetics is the study of how people respond differently to drug therapy based on their unique genetic makeup.  Genetic variations cause differences in the expression of various enzymes involved in drug metabolism.

Health #economic studies ha ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Pharmacogenetics is the study of how people respond differently to drug therapy based on their unique genetic makeup.  Genetic variations cause differences in the expression of various enzymes involved in drug metabolism.

Health #economic studies have shown that the use of pharmacogenetic testing in clinical practice results in better outcomes  - by a variety of metrics.

Are payors interested in these data?  Of course they are.  Better outcomes generally save money as well.  
]]></itunes:summary>
      <itunes:duration>0:00:58</itunes:duration>
      <itunes:length>924322</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[KRISTINE ASHCRAFT, CEO OF YOUSCRIPT - Preview 3]]></title>
      <description><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.

Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.
]]></description>
      <guid isPermaLink="false">6CW9AB2P-53FPQFR</guid>
      <pubDate>Sat, 18 Apr 2020 03:21:08 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/kristine-prev-3-.mp3" length="538383" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxici ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.

Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.
]]></itunes:summary>
      <itunes:duration>0:00:34</itunes:duration>
      <itunes:length>538383</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[KRISTINE ASHCRAFT, CEO OF YOUSCRIPT - PREVIEW 2]]></title>
      <description><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.

Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.
]]></description>
      <guid isPermaLink="false">EUA0PSQM-0442T9</guid>
      <pubDate>Sat, 18 Apr 2020 03:19:47 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/kristine-prev-2-.mp3" length="925383" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxici ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.

Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.
]]></itunes:summary>
      <itunes:duration>0:00:57</itunes:duration>
      <itunes:length>925383</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[KRISTINE ASHCRAFT, CEO OF YOUSCRIPT - Preview 1]]></title>
      <description><![CDATA[How has pharmacogenetic testing evolved over the past 20 years?

We've moved from a very expensive single-gene testing model focused on drug - gene pairs to a more cost-effective multigene panel approach, which can provide significantly more information.

Kristine Ashcraft, CEO of YouScript, which offers a unique combination of pharmacogenetic information and EMR-integrated software, joins us this week on The Personalized Diagnostics Podcast.
]]></description>
      <guid isPermaLink="false">GODRBVOO-12A9K9</guid>
      <pubDate>Sat, 18 Apr 2020 03:18:32 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/kristine-prev1-.mp3" length="1212820" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[How has pharmacogenetic testing evolved over the past 20 years?

We've moved from a very expensive single-gene testing model focused on drug - gene pairs to a more cost-effective multigene panel approach, which can provide significantly more informat ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[How has pharmacogenetic testing evolved over the past 20 years?

We've moved from a very expensive single-gene testing model focused on drug - gene pairs to a more cost-effective multigene panel approach, which can provide significantly more information.

Kristine Ashcraft, CEO of YouScript, which offers a unique combination of pharmacogenetic information and EMR-integrated software, joins us this week on The Personalized Diagnostics Podcast.
]]></itunes:summary>
      <itunes:duration>0:01:17</itunes:duration>
      <itunes:length>1212820</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Kristine Ashcraft, CEO of YouScript - Episode 14]]></title>
      <description><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.

Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.

Our guest today is out to change that.  Kristine Ashcraft is CEO of YouScript, a company offering unique pharmacogenetic information and an Electronic Medical Record integraed software solution.
]]></description>
      <guid isPermaLink="false">FCYKQBC7-3VJ9K9</guid>
      <pubDate>Thu, 26 Mar 2020 21:08:55 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Kristine-Ashcraft.mp3" length="21622531" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxici ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.

Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.

Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.

Our guest today is out to change that.  Kristine Ashcraft is CEO of YouScript, a company offering unique pharmacogenetic information and an Electronic Medical Record integraed software solution.
]]></itunes:summary>
      <itunes:duration>0:22:53</itunes:duration>
      <itunes:length>21622531</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[PRASUN MISHRA, PHD, AAPM CORONAVIRUS TASKFORCE - PREVIEW 3]]></title>
      <description><![CDATA[Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM) and chair of the AAPM Coronavirus Taskforce (ACT) discussing the unique challenges of a fighting a pandemic in this modern era of globalization, frequent travel and porous national borders in which the world has become "one big home"]]></description>
      <guid isPermaLink="false">FB1E3UKQ-D50ZFR</guid>
      <pubDate>Thu, 26 Mar 2020 19:11:04 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/prasun-prev-3-.mp3" length="189539" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM) and chair of the AAPM Coronavirus Taskforce (ACT) discussing the unique challenges of a fighting a pandemic in this modern era of globalization, frequent ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM) and chair of the AAPM Coronavirus Taskforce (ACT) discussing the unique challenges of a fighting a pandemic in this modern era of globalization, frequent travel and porous national borders in which the world has become "one big home"]]></itunes:summary>
      <itunes:duration>0:00:20</itunes:duration>
      <itunes:length>189539</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Prasun Mishra, PHD, AAPM Coronavirus taskforce - Preview 2 ]]></title>
      <description><![CDATA[Of the measures available to us to combat #covid19, what should be our priority?]]></description>
      <guid isPermaLink="false">AYBVGCJK-2FBT9</guid>
      <pubDate>Thu, 26 Mar 2020 19:08:26 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/prasun-prev-2-.mp3" length="432647" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Of the measures available to us to combat #covid19, what should be our priority?]]></itunes:subtitle>
      <itunes:summary><![CDATA[Of the measures available to us to combat #covid19, what should be our priority?]]></itunes:summary>
      <itunes:duration>0:00:44</itunes:duration>
      <itunes:length>432647</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Prasun Mishra, PHD, AAPM Coronavirus Taskforce  - Preview 1]]></title>
      <description><![CDATA[Rahm Emanuel, Chief of Staff to Barack Obama and Mayor of City of Chicago famously said, "Never let a crisis go wasted."

What lessons can we learn from the current Covid-19 crisis?

Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM) and chair of the AAPM Coronavirus Taskforce (ACT)
]]></description>
      <guid isPermaLink="false">CSKKMLXD-4BCSOR</guid>
      <pubDate>Thu, 26 Mar 2020 19:03:44 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/prasun-prev-1.mp3" length="612915" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Rahm Emanuel, Chief of Staff to Barack Obama and Mayor of City of Chicago famously said, "Never let a crisis go wasted."

What lessons can we learn from the current Covid-19 crisis?

Prasun Mishra, Ph.D. President and CEO of the American Association  ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Rahm Emanuel, Chief of Staff to Barack Obama and Mayor of City of Chicago famously said, "Never let a crisis go wasted."

What lessons can we learn from the current Covid-19 crisis?

Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM) and chair of the AAPM Coronavirus Taskforce (ACT)
]]></itunes:summary>
      <itunes:duration>0:01:01</itunes:duration>
      <itunes:length>612915</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine  and chair of the  AAPM Coronavirus Taskforce (ACT)  - Episode 13]]></title>
      <description><![CDATA[Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM)- and chair of the  AAPM Coronavirus Taskforce (ACT) joins us on the The Personalized Diagnostics Podcast during this global pandemic.

 - Is the novel coronavirus mutating and has a potential to become more contagious?

- Strategies to combat COVID-19?

- Will things get better before they get worse?

- Therapies in development for the novel coronavirus?

- The story behind formation of ACT- AAPMs Coronavirus Taskforce

- What lessons we'll be able to learn from this crisis?]]></description>
      <guid isPermaLink="false">FE4R6WC8-8ILIK9</guid>
      <pubDate>Tue, 17 Mar 2020 00:37:26 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/AAPM-ACT-Task-force.mp3" length="19714267" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM)- and chair of the  AAPM Coronavirus Taskforce (ACT) joins us on the The Personalized Diagnostics Podcast during this global pandemic.

 - Is the novel co ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM)- and chair of the  AAPM Coronavirus Taskforce (ACT) joins us on the The Personalized Diagnostics Podcast during this global pandemic.

 - Is the novel coronavirus mutating and has a potential to become more contagious?

- Strategies to combat COVID-19?

- Will things get better before they get worse?

- Therapies in development for the novel coronavirus?

- The story behind formation of ACT- AAPMs Coronavirus Taskforce

- What lessons we'll be able to learn from this crisis?]]></itunes:summary>
      <itunes:duration>0:30:55</itunes:duration>
      <itunes:length>19714267</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[KATHLEEN WALCH AND RON SCHMELZER, COGNILYTICA - PREVIEW 3]]></title>
      <description><![CDATA[Will people lose their jobs due to increased #automation and artificial intelligence applications?

"There's a difference between your 'work' and your 'job.' "

The tasks you perform or the #work you do may not be the essence of your job.

"There is a well-known 'Amazon paradox,' which is that as Amazon was increasing the amount of automation in their warehouses and distribution facilities, they were actually increasing their hiring rate."]]></description>
      <guid isPermaLink="false">DKYI704N-X3WHFR</guid>
      <pubDate>Tue, 17 Mar 2020 00:35:58 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/cognilytica-prev-3.mp3" length="740416" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Will people lose their jobs due to increased #automation and artificial intelligence applications?

"There's a difference between your 'work' and your 'job.' "

The tasks you perform or the #work you do may not be the essence of your job.

"There is  ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Will people lose their jobs due to increased #automation and artificial intelligence applications?

"There's a difference between your 'work' and your 'job.' "

The tasks you perform or the #work you do may not be the essence of your job.

"There is a well-known 'Amazon paradox,' which is that as Amazon was increasing the amount of automation in their warehouses and distribution facilities, they were actually increasing their hiring rate."]]></itunes:summary>
      <itunes:duration>0:00:51</itunes:duration>
      <itunes:length>740416</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[KATHLEEN WALCH AND RON SCHMELZER, COGNILYTICA - PREVIEW 2]]></title>
      <description><![CDATA[What are some of the misconceptions surrounding #AI?

A focus on “artificial general intelligence” – the stuff of 1950’s science fiction and concerns of robots taking over the world -  “What could you do if you had a machine that is able to act and think and be just like a human,” seems to be going away somewhat.

This #focus is being replaced by realistic concerns and a focus on what it is possible to achieve with specific narrow applications that can solve real problems today - not at some point in the future.]]></description>
      <guid isPermaLink="false">2908M2D5-RFS3V7V</guid>
      <pubDate>Tue, 17 Mar 2020 00:34:26 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/cognilytica-prev-2.mp3" length="474147" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[What are some of the misconceptions surrounding #AI?

A focus on “artificial general intelligence” – the stuff of 1950’s science fiction and concerns of robots taking over the world -  “What could you do if you had a machine that is able to act and t ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[What are some of the misconceptions surrounding #AI?

A focus on “artificial general intelligence” – the stuff of 1950’s science fiction and concerns of robots taking over the world -  “What could you do if you had a machine that is able to act and think and be just like a human,” seems to be going away somewhat.

This #focus is being replaced by realistic concerns and a focus on what it is possible to achieve with specific narrow applications that can solve real problems today - not at some point in the future.]]></itunes:summary>
      <itunes:duration>0:00:36</itunes:duration>
      <itunes:length>474147</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[KATHLEEN WALCH AND RON SCHMELZER, COGNILYTICA - Preview 1]]></title>
      <description><![CDATA[There’s still a lot of misunderstanding surrounding Artificial #Intelligence. When two people talk about #AI, they are quite likely not even talking about the same thing.

To eliminate confusion and facilitate understanding, Cognilytica focuses on the 7 Patterns of AI:

Conversation and Human Interaction
Recognition
Patterns and Anomalies
Predictive Analytics
Autonomous Systems
Hyperpersonalization 
Goal Directed Systems
]]></description>
      <guid isPermaLink="false">ARPF3CAQ-PGGY14I</guid>
      <pubDate>Tue, 17 Mar 2020 00:33:19 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/cognilytica-prev-1.mp3" length="1272427" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[There’s still a lot of misunderstanding surrounding Artificial #Intelligence. When two people talk about #AI, they are quite likely not even talking about the same thing.

To eliminate confusion and facilitate understanding, Cognilytica focuses on th ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[There’s still a lot of misunderstanding surrounding Artificial #Intelligence. When two people talk about #AI, they are quite likely not even talking about the same thing.

To eliminate confusion and facilitate understanding, Cognilytica focuses on the 7 Patterns of AI:

Conversation and Human Interaction
Recognition
Patterns and Anomalies
Predictive Analytics
Autonomous Systems
Hyperpersonalization 
Goal Directed Systems
]]></itunes:summary>
      <itunes:duration>0:01:29</itunes:duration>
      <itunes:length>1272427</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Kathleen Walch and Ron Schmelzer,  Cognilytica - The 7 patterns of AI - Episode 12]]></title>
      <description><![CDATA[Kathleen Walch and Ron Schmelzer, managing partners  of the Artificial Intelligence-focused advisory firm Cognilytica

The 7 patterns of #AI

"How can we regulate something that is continuously evolving?"

"Are we focusing on the wrong thing?"

"Where's my flying car?"

and much more...  That's this week on the Personalized Diagnostics Podcast]]></description>
      <guid isPermaLink="false">8C1JBETK-7TLNMI</guid>
      <pubDate>Thu, 12 Mar 2020 04:58:11 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Kathleen-and-Ron.mp3" length="28731139" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Kathleen Walch and Ron Schmelzer, managing partners  of the Artificial Intelligence-focused advisory firm Cognilytica

The 7 patterns of #AI

"How can we regulate something that is continuously evolving?"

"Are we focusing on the wrong thing?"

"Wher ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Kathleen Walch and Ron Schmelzer, managing partners  of the Artificial Intelligence-focused advisory firm Cognilytica

The 7 patterns of #AI

"How can we regulate something that is continuously evolving?"

"Are we focusing on the wrong thing?"

"Where's my flying car?"

and much more...  That's this week on the Personalized Diagnostics Podcast]]></itunes:summary>
      <itunes:duration>0:34:54</itunes:duration>
      <itunes:length>28731139</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Rakesh Nagarajan , MD, PhD, Preview 4]]></title>
      <description><![CDATA[One of the promises of precision #medicine is the ability to iterate and incorporate new #information in real-time, rather than having to wait months or years to incorporate new findings into patient treatment decisions.

Have we reached the point where information or data that we observe in patients this week can be used to enhance our ability to treat patients next week?]]></description>
      <guid isPermaLink="false">7T931Y08-PO2BJ4I</guid>
      <pubDate>Thu, 12 Mar 2020 04:52:30 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rakesh-prev-4-.mp3" length="1013071" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[One of the promises of precision #medicine is the ability to iterate and incorporate new #information in real-time, rather than having to wait months or years to incorporate new findings into patient treatment decisions.

Have we reached the point wh ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[One of the promises of precision #medicine is the ability to iterate and incorporate new #information in real-time, rather than having to wait months or years to incorporate new findings into patient treatment decisions.

Have we reached the point where information or data that we observe in patients this week can be used to enhance our ability to treat patients next week?]]></itunes:summary>
      <itunes:duration>0:01:14</itunes:duration>
      <itunes:length>1013071</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[RAKESH NAGARAJAN, MD, PHD - PREVIEW 3]]></title>
      <description><![CDATA["We're helping customers internalize next generation #sequencing for clinical use... in virtually every market segment."

PierianDx is on a mission to democratize next generation sequencing and #genomics in medicine worldwide.]]></description>
      <guid isPermaLink="false">53RJDEE7-T5IPB9</guid>
      <pubDate>Thu, 12 Mar 2020 04:51:02 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rakesh-prev-3.mp3" length="842549" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["We're helping customers internalize next generation #sequencing for clinical use... in virtually every market segment."

PierianDx is on a mission to democratize next generation sequencing and #genomics in medicine worldwide.]]></itunes:subtitle>
      <itunes:summary><![CDATA["We're helping customers internalize next generation #sequencing for clinical use... in virtually every market segment."

PierianDx is on a mission to democratize next generation sequencing and #genomics in medicine worldwide.]]></itunes:summary>
      <itunes:duration>0:01:03</itunes:duration>
      <itunes:length>842549</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[RAKESH NAGARAJAN, MD, PHD - PREVIEW 2]]></title>
      <description><![CDATA[In Greek mythology, the Pierian Spring of Macedonia was sacred to the Muses. It was believed that drinking from it would bring you great knowledge and #inspiration.  

As the metaphorical source of knowledge of art and #science, it was popularized in Alexander Pope's poem "An Essay on Criticism" (1711): 

"A little learning is a dang'rous thing;
Drink deep, or taste not the Pierian spring."]]></description>
      <guid isPermaLink="false">FYN9NWTH-BUIK9</guid>
      <pubDate>Thu, 12 Mar 2020 04:49:58 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rakesh-prev-2-.mp3" length="375861" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[In Greek mythology, the Pierian Spring of Macedonia was sacred to the Muses. It was believed that drinking from it would bring you great knowledge and #inspiration.  

As the metaphorical source of knowledge of art and #science, it was popularized in ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[In Greek mythology, the Pierian Spring of Macedonia was sacred to the Muses. It was believed that drinking from it would bring you great knowledge and #inspiration.  

As the metaphorical source of knowledge of art and #science, it was popularized in Alexander Pope's poem "An Essay on Criticism" (1711): 

"A little learning is a dang'rous thing;
Drink deep, or taste not the Pierian spring."]]></itunes:summary>
      <itunes:duration>0:00:28</itunes:duration>
      <itunes:length>375861</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[RAKESH NAGARAJAN, MD, PHD - Preview 1]]></title>
      <description><![CDATA[Despite tremendous advances in #sequencing technologies, informatics and computational power, there still remains a fair degree of subjectivity in genomics and personalized medicine.

It takes a team of laboratory scientists, informaticians, variant scientists and physicians to develop and perform assays and formulate treatment decisions for patients.]]></description>
      <guid isPermaLink="false">CXAGTN27-6RMS4I</guid>
      <pubDate>Thu, 12 Mar 2020 04:48:26 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rakesh-prev-1-.mp3" length="542741" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Despite tremendous advances in #sequencing technologies, informatics and computational power, there still remains a fair degree of subjectivity in genomics and personalized medicine.

It takes a team of laboratory scientists, informaticians, variant  ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Despite tremendous advances in #sequencing technologies, informatics and computational power, there still remains a fair degree of subjectivity in genomics and personalized medicine.

It takes a team of laboratory scientists, informaticians, variant scientists and physicians to develop and perform assays and formulate treatment decisions for patients.]]></itunes:summary>
      <itunes:duration>0:00:39</itunes:duration>
      <itunes:length>542741</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Rakesh Nagarajan, MD, PhD, Founder and Executive Chairman of PierianDx - Democratizing Next Generation Sequencing - Episode 11]]></title>
      <description><![CDATA[In Greek mythology, the Pierian Spring of Macedonia was sacred to the Muses. It was believed that drinking from it would bring you great knowledge and inspiration.  

As the metaphorical source of knowledge of art and science, it was popularized in Alexander Pope's poem "An Essay on Criticism" (1711): 

"A little learning is a dang'rous thing;
Drink deep, or taste not the Pierian spring:

It takes a team of laboratory scientists, informaticians, variant scientists and physicians to develop and perform assays and formulate treatment decisions for patients.

Rakesh Nagarajan, MD, PhD, of PierianDx joins us to discuss their mission to democratize next generation sequencing.]]></description>
      <guid isPermaLink="false">10RWKRIM-4R7R2J4</guid>
      <pubDate>Fri, 06 Mar 2020 02:10:00 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Rakesh-Nagarajan.mp3" length="19904299" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[In Greek mythology, the Pierian Spring of Macedonia was sacred to the Muses. It was believed that drinking from it would bring you great knowledge and inspiration.  

As the metaphorical source of knowledge of art and science, it was popularized in A ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[In Greek mythology, the Pierian Spring of Macedonia was sacred to the Muses. It was believed that drinking from it would bring you great knowledge and inspiration.  

As the metaphorical source of knowledge of art and science, it was popularized in Alexander Pope's poem "An Essay on Criticism" (1711): 

"A little learning is a dang'rous thing;
Drink deep, or taste not the Pierian spring:

It takes a team of laboratory scientists, informaticians, variant scientists and physicians to develop and perform assays and formulate treatment decisions for patients.

Rakesh Nagarajan, MD, PhD, of PierianDx joins us to discuss their mission to democratize next generation sequencing.]]></itunes:summary>
      <itunes:duration>0:24:10</itunes:duration>
      <itunes:length>19904299</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[SUNANDINI CHOPRA, PHD, AI FOR THE REST OF US - PREVIEW 3]]></title>
      <description><![CDATA[Will AI applications be limited to research and discovery and development of drugs and diagnostics?

What about post-launch and real-world experience?

"The observational study space is fairly disorganized and could greatly benefit from digitization and machine learning."
]]></description>
      <guid isPermaLink="false">JEHM1AR9-EI2J4I</guid>
      <pubDate>Fri, 06 Mar 2020 02:00:36 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/sun-prev-3-.mp3" length="488758" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Will AI applications be limited to research and discovery and development of drugs and diagnostics?

What about post-launch and real-world experience?

"The observational study space is fairly disorganized and could greatly benefit from digitization  ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Will AI applications be limited to research and discovery and development of drugs and diagnostics?

What about post-launch and real-world experience?

"The observational study space is fairly disorganized and could greatly benefit from digitization and machine learning."
]]></itunes:summary>
      <itunes:duration>0:00:54</itunes:duration>
      <itunes:length>488758</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[SUNANDINI CHOPRA, PHD, AI FOR THE REST OF US - PREVIEW 2]]></title>
      <description><![CDATA[What are patient avatars?

Imagine being able to understand drug efficacy and toxicities without having to involve actual patients.]]></description>
      <guid isPermaLink="false">C389AVSJ-TQPVI</guid>
      <pubDate>Fri, 06 Mar 2020 01:57:58 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/sun-prev-2.mp3" length="392120" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[What are patient avatars?

Imagine being able to understand drug efficacy and toxicities without having to involve actual patients.]]></itunes:subtitle>
      <itunes:summary><![CDATA[What are patient avatars?

Imagine being able to understand drug efficacy and toxicities without having to involve actual patients.]]></itunes:summary>
      <itunes:duration>0:00:43</itunes:duration>
      <itunes:length>392120</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Sunandini Chopra, PhD, AI For The Rest of Us - Preview 1]]></title>
      <description><![CDATA[All of this talk about #AI can be confusing and intimidating.

What is it?
How does it work?
What are applications in #healthcare going to look like?
Is it going to take away my job?]]></description>
      <guid isPermaLink="false">HPB257SP-ZTO6R</guid>
      <pubDate>Fri, 06 Mar 2020 01:56:36 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/sun-prev1-.mp3" length="513989" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[All of this talk about #AI can be confusing and intimidating.

What is it?
How does it work?
What are applications in #healthcare going to look like?
Is it going to take away my job?]]></itunes:subtitle>
      <itunes:summary><![CDATA[All of this talk about #AI can be confusing and intimidating.

What is it?
How does it work?
What are applications in #healthcare going to look like?
Is it going to take away my job?]]></itunes:summary>
      <itunes:duration>0:00:36</itunes:duration>
      <itunes:length>513989</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Sunandini Chopra, PhD, AI for the Rest of Us - Episode 10]]></title>
      <description><![CDATA[All of this talk about Artificial Intelligence can be confusing and intimidating.

What is it?
How does it work?
What are applications in healthcare going to look like?
Is it going to take away my job?

Finally, AI for the Rest of Us.  Sunandini Chopra, PhD,  joins us this week.]]></description>
      <guid isPermaLink="false">FQSWZL1R-MEU3DI</guid>
      <pubDate>Wed, 26 Feb 2020 17:09:49 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Sunandini-Chopra.mp3" length="14264707" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[All of this talk about Artificial Intelligence can be confusing and intimidating.

What is it?
How does it work?
What are applications in healthcare going to look like?
Is it going to take away my job?

Finally, AI for the Rest of Us.  Sunandini Chop ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[All of this talk about Artificial Intelligence can be confusing and intimidating.

What is it?
How does it work?
What are applications in healthcare going to look like?
Is it going to take away my job?

Finally, AI for the Rest of Us.  Sunandini Chopra, PhD,  joins us this week.]]></itunes:summary>
      <itunes:duration>0:22:53</itunes:duration>
      <itunes:length>14264707</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Michael Bonham , MD, PHD - part II - Preview 3]]></title>
      <description><![CDATA["It doesn't give you a diagnosis, but it gives you additional information... and the hope is that all pathologists will have the same information." ]]></description>
      <guid isPermaLink="false">1TUM9AMX-P33OW29</guid>
      <pubDate>Mon, 24 Feb 2020 04:15:40 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/mike-ep-2-prev-3.mp3" length="611858" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["It doesn't give you a diagnosis, but it gives you additional information... and the hope is that all pathologists will have the same information." ]]></itunes:subtitle>
      <itunes:summary><![CDATA["It doesn't give you a diagnosis, but it gives you additional information... and the hope is that all pathologists will have the same information." ]]></itunes:summary>
      <itunes:duration>0:01:02</itunes:duration>
      <itunes:length>611858</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Michael Bonham , MD, PHD - part II - Preview 2]]></title>
      <description><![CDATA["In the same way that when you listen to Pandora, it knows what song you're going to like..."]]></description>
      <guid isPermaLink="false">8QVGB43A-1DOBT9</guid>
      <pubDate>Mon, 24 Feb 2020 04:13:39 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/mike-ep-2-prev-2.mp3" length="595196" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["In the same way that when you listen to Pandora, it knows what song you're going to like..."]]></itunes:subtitle>
      <itunes:summary><![CDATA["In the same way that when you listen to Pandora, it knows what song you're going to like..."]]></itunes:summary>
      <itunes:duration>0:00:59</itunes:duration>
      <itunes:length>595196</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Michael Bonham , MD, PHD - part II - Preview 1]]></title>
      <description><![CDATA[A confluence of factors will drive the shift to digital pathology.]]></description>
      <guid isPermaLink="false">CI7CX593-45TGLDI</guid>
      <pubDate>Mon, 24 Feb 2020 04:12:04 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/mike-ep-2-prev-1.mp3" length="816602" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[A confluence of factors will drive the shift to digital pathology.]]></itunes:subtitle>
      <itunes:summary><![CDATA[A confluence of factors will drive the shift to digital pathology.]]></itunes:summary>
      <itunes:duration>0:01:17</itunes:duration>
      <itunes:length>816602</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Michael Bonham MD,PhD, Chief Medical Officer of Proscia - part ii - Have we reached the tipping point? - Episode 9]]></title>
      <description><![CDATA[Michael Bonham MD,PhD, Chief Medical Officer of Proscia is back! 

 Last time we talked about how pathologists are using the same technology – the light microscope – that they have been for the past 150 years.  

The rate of converting to a fully digital system, particularly in the United States, is abysmally low.

With a global shortage of pathologists and regulatory barriers coming down, could we finally be reaching a tipping point?  

Could #AI be the missing link that will push us over the edge?
]]></description>
      <guid isPermaLink="false">H37URBUU-1PP66R</guid>
      <pubDate>Thu, 20 Feb 2020 05:29:23 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/mike-bonham-part-2.mp3" length="12830899" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Michael Bonham MD,PhD, Chief Medical Officer of Proscia is back! 

 Last time we talked about how pathologists are using the same technology – the light microscope – that they have been for the past 150 years.  

The rate of converting to a fully dig ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Michael Bonham MD,PhD, Chief Medical Officer of Proscia is back! 

 Last time we talked about how pathologists are using the same technology – the light microscope – that they have been for the past 150 years.  

The rate of converting to a fully digital system, particularly in the United States, is abysmally low.

With a global shortage of pathologists and regulatory barriers coming down, could we finally be reaching a tipping point?  

Could #AI be the missing link that will push us over the edge?
]]></itunes:summary>
      <itunes:duration>0:19:30</itunes:duration>
      <itunes:length>12830899</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[RAFAEL ROSENGARTEN, PHD - PREVIEW 3]]></title>
      <description><![CDATA[What role will AI play in the development of new diagnostics?]]></description>
      <guid isPermaLink="false">8YILI11X-KXOGVI</guid>
      <pubDate>Thu, 20 Feb 2020 05:24:12 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rafael-prev-3.mp3" length="560378" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[What role will AI play in the development of new diagnostics?]]></itunes:subtitle>
      <itunes:summary><![CDATA[What role will AI play in the development of new diagnostics?]]></itunes:summary>
      <itunes:duration>0:00:41</itunes:duration>
      <itunes:length>560378</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[RAFAEL ROSENGARTEN, PHD - PREVIEW 2]]></title>
      <description><![CDATA["AI systems in healthcare are going to be under a huge amount of scrutiny."]]></description>
      <guid isPermaLink="false">U1ZGMOI-6O3CJTT9</guid>
      <pubDate>Thu, 20 Feb 2020 05:23:09 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rafael-prev-2.mp3" length="715204" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["AI systems in healthcare are going to be under a huge amount of scrutiny."]]></itunes:subtitle>
      <itunes:summary><![CDATA["AI systems in healthcare are going to be under a huge amount of scrutiny."]]></itunes:summary>
      <itunes:duration>0:00:52</itunes:duration>
      <itunes:length>715204</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Rafael Rosengarten, PhD - Preview 1]]></title>
      <description><![CDATA[We've all heard the hype.  But what exactly is AI?]]></description>
      <guid isPermaLink="false">6SWJVTEP-E5KLNMI</guid>
      <pubDate>Thu, 20 Feb 2020 05:21:49 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/rafael-prev-1.mp3" length="674569" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[We've all heard the hype.  But what exactly is AI?]]></itunes:subtitle>
      <itunes:summary><![CDATA[We've all heard the hype.  But what exactly is AI?]]></itunes:summary>
      <itunes:duration>0:00:49</itunes:duration>
      <itunes:length>674569</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Rafael Rosengarten, PhD, CEO of Genialis and founding member of the Alliance for AI in Healthcare - Episode 8]]></title>
      <description><![CDATA[We've all heard the hype.  "There's no area of healthcare that will not be affected by AI."  "Those that fail to embrace AI will be left behind by those that do."

But what exactly is AI and how will it impact healthcare?

Rafael Rosengarten is CEO of Genialis and founding member of the Alliance for Artificial Intelligence in Healthcare.]]></description>
      <guid isPermaLink="false">8EDSAJRJ-GLJ714I</guid>
      <pubDate>Tue, 11 Feb 2020 17:52:58 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Rafael-Rosengarten.mp3" length="20764675" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[We've all heard the hype.  "There's no area of healthcare that will not be affected by AI."  "Those that fail to embrace AI will be left behind by those that do."

But what exactly is AI and how will it impact healthcare?

Rafael Rosengarten is CEO o ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[We've all heard the hype.  "There's no area of healthcare that will not be affected by AI."  "Those that fail to embrace AI will be left behind by those that do."

But what exactly is AI and how will it impact healthcare?

Rafael Rosengarten is CEO of Genialis and founding member of the Alliance for Artificial Intelligence in Healthcare.]]></itunes:summary>
      <itunes:duration>0:25:13</itunes:duration>
      <itunes:length>20764675</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Michael Bonham, MD, PhD, CMO of Proscia, The Promise of Digital Pathology - Episode 7]]></title>
      <description><![CDATA[Pathologists have used largely the same technology to make diagnoses since the late 1800's.  Will Pathology be able to go fully digital and enter the 21st century?  

Michael Bonham, MD, PhD, Chief Medical Officer of Proscia, joins us to discuss the promise of digital pathology.]]></description>
      <guid isPermaLink="false">GB08ZKJZ-ESTT9</guid>
      <pubDate>Tue, 04 Feb 2020 16:39:40 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/mike-bonham.mp3" length="12403819" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Pathologists have used largely the same technology to make diagnoses since the late 1800's.  Will Pathology be able to go fully digital and enter the 21st century?  

Michael Bonham, MD, PhD, Chief Medical Officer of Proscia, joins us to discuss the  ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Pathologists have used largely the same technology to make diagnoses since the late 1800's.  Will Pathology be able to go fully digital and enter the 21st century?  

Michael Bonham, MD, PhD, Chief Medical Officer of Proscia, joins us to discuss the promise of digital pathology.]]></itunes:summary>
      <itunes:duration>0:18:59</itunes:duration>
      <itunes:length>12403819</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Clifford Morris, PhD - Preview 3]]></title>
      <description><![CDATA["So many lab test are just done...and nothing gets done about them."]]></description>
      <guid isPermaLink="false">H5N22JUV-9CZ0K9</guid>
      <pubDate>Tue, 04 Feb 2020 16:29:46 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/clifford-prev-3.mp3" length="335602" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["So many lab test are just done...and nothing gets done about them."]]></itunes:subtitle>
      <itunes:summary><![CDATA["So many lab test are just done...and nothing gets done about them."]]></itunes:summary>
      <itunes:duration>0:00:30</itunes:duration>
      <itunes:length>335602</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Clifford Morris, PhD - Preview 2]]></title>
      <description><![CDATA["Having specifics is really the whole point of using AI...not to get general trends."]]></description>
      <guid isPermaLink="false">XDOYGEH-95CXFLXR</guid>
      <pubDate>Tue, 04 Feb 2020 16:28:34 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/clifford-prev-2.mp3" length="593641" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["Having specifics is really the whole point of using AI...not to get general trends."]]></itunes:subtitle>
      <itunes:summary><![CDATA["Having specifics is really the whole point of using AI...not to get general trends."]]></itunes:summary>
      <itunes:duration>0:00:54</itunes:duration>
      <itunes:length>593641</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Clifford Morris, PhD - Preview 1]]></title>
      <description><![CDATA["Metabolomics, we really see as the apogee of all the -omics."]]></description>
      <guid isPermaLink="false">JWH0GG55-U5L8FR</guid>
      <pubDate>Tue, 04 Feb 2020 16:24:37 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/clifford-prev1.mp3" length="815292" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["Metabolomics, we really see as the apogee of all the -omics."]]></itunes:subtitle>
      <itunes:summary><![CDATA["Metabolomics, we really see as the apogee of all the -omics."]]></itunes:summary>
      <itunes:duration>0:01:13</itunes:duration>
      <itunes:length>815292</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Clifford Morris, PhD, Laboratory Medicine 2.0 - Episode 6]]></title>
      <description><![CDATA[Laboratory Medicine 2.0 holds much promise, but we have many challenges to overcome before it is a reality.   

Will we be able to move away from volume based testing to value based testing?  Will we be able to show definitively that patient outcomes and overall levels of health can be improved using laboratory methods? And will we be able to move away from sick care and more towards a system of wellness care?]]></description>
      <guid isPermaLink="false">6FTGRDFH-95ASJOR</guid>
      <pubDate>Wed, 29 Jan 2020 18:54:19 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Clifford-Morris.mp3" length="19147507" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Laboratory Medicine 2.0 holds much promise, but we have many challenges to overcome before it is a reality.   

Will we be able to move away from volume based testing to value based testing?  Will we be able to show definitively that patient outcomes ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Laboratory Medicine 2.0 holds much promise, but we have many challenges to overcome before it is a reality.   

Will we be able to move away from volume based testing to value based testing?  Will we be able to show definitively that patient outcomes and overall levels of health can be improved using laboratory methods? And will we be able to move away from sick care and more towards a system of wellness care?]]></itunes:summary>
      <itunes:duration>0:27:36</itunes:duration>
      <itunes:length>19147507</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Julie Eggington, MS, PhD - Preview 3]]></title>
      <description><![CDATA[Variants of Uncertain Significance (VUS) cause tension but really shouldn't.]]></description>
      <guid isPermaLink="false">7TKFI8G1-QFWP14I</guid>
      <pubDate>Wed, 29 Jan 2020 18:47:22 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/julie-prv3.mp3" length="508091" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Variants of Uncertain Significance (VUS) cause tension but really shouldn't.]]></itunes:subtitle>
      <itunes:summary><![CDATA[Variants of Uncertain Significance (VUS) cause tension but really shouldn't.]]></itunes:summary>
      <itunes:duration>0:00:33</itunes:duration>
      <itunes:length>508091</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Julie Eggington, MS, PhD - Preview 2]]></title>
      <description><![CDATA["Hang on! genetic variants are actually very, very common."]]></description>
      <guid isPermaLink="false">DODYB6LT-GAXLXR</guid>
      <pubDate>Wed, 29 Jan 2020 18:46:16 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/julie-prev2.mp3" length="857235" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["Hang on! genetic variants are actually very, very common."]]></itunes:subtitle>
      <itunes:summary><![CDATA["Hang on! genetic variants are actually very, very common."]]></itunes:summary>
      <itunes:duration>0:00:59</itunes:duration>
      <itunes:length>857235</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Julie Eggington, MS, PhD - Preview 1]]></title>
      <description><![CDATA[We saw tension between investor demands which is profitability and the interests of patients which is accuracy.]]></description>
      <guid isPermaLink="false">HF2R67EI-TDQUXR</guid>
      <pubDate>Wed, 29 Jan 2020 18:44:35 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/julie-prev-1.mp3" length="662202" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[We saw tension between investor demands which is profitability and the interests of patients which is accuracy.]]></itunes:subtitle>
      <itunes:summary><![CDATA[We saw tension between investor demands which is profitability and the interests of patients which is accuracy.]]></itunes:summary>
      <itunes:duration>0:00:45</itunes:duration>
      <itunes:length>662202</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Julie Eggington, MS, PhD, Center for Genomic Interpretation - Episode 5]]></title>
      <description><![CDATA[We can now test anyone for nearly any genetic mutation or alteration.  What could possibly go wrong?

Julie Eggington, MS, PhD, co-founder and CEO of Center for Genomic Interpretation joins us this week.]]></description>
      <guid isPermaLink="false">JV2WZOEK-5A5RK9</guid>
      <pubDate>Tue, 21 Jan 2020 18:18:05 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Julie-Eggington.mp3" length="25365595" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[We can now test anyone for nearly any genetic mutation or alteration.  What could possibly go wrong?

Julie Eggington, MS, PhD, co-founder and CEO of Center for Genomic Interpretation joins us this week.]]></itunes:subtitle>
      <itunes:summary><![CDATA[We can now test anyone for nearly any genetic mutation or alteration.  What could possibly go wrong?

Julie Eggington, MS, PhD, co-founder and CEO of Center for Genomic Interpretation joins us this week.]]></itunes:summary>
      <itunes:duration>0:28:41</itunes:duration>
      <itunes:length>25365595</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Hannah Mamuszka, CEO of Alva10 - Preview 3]]></title>
      <description><![CDATA[What do we have to look forward to in the coming decade?]]></description>
      <guid isPermaLink="false">BCFJ804R-Z4U0UDI</guid>
      <pubDate>Mon, 20 Jan 2020 23:44:08 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/hannah-promo-3.mp3" length="374079" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[What do we have to look forward to in the coming decade?]]></itunes:subtitle>
      <itunes:summary><![CDATA[What do we have to look forward to in the coming decade?]]></itunes:summary>
      <itunes:duration>0:00:26</itunes:duration>
      <itunes:length>374079</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Hannah Mamuszka, CEO of Alva10 - Preview 2]]></title>
      <description><![CDATA[How can we spur innovation?]]></description>
      <guid isPermaLink="false">FZCB9J5K-L2QPVI</guid>
      <pubDate>Mon, 20 Jan 2020 23:43:24 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/hannah-prev-2.mp3" length="746837" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[How can we spur innovation?]]></itunes:subtitle>
      <itunes:summary><![CDATA[How can we spur innovation?]]></itunes:summary>
      <itunes:duration>0:00:53</itunes:duration>
      <itunes:length>746837</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Hannah Mamuszka, CEO of Alva10 - Preview 1]]></title>
      <description><![CDATA[Who is the customer?]]></description>
      <guid isPermaLink="false">FZSN3RW5-W29</guid>
      <pubDate>Mon, 20 Jan 2020 23:41:40 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/hannah-prev-1.mp3" length="695512" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Who is the customer?]]></itunes:subtitle>
      <itunes:summary><![CDATA[Who is the customer?]]></itunes:summary>
      <itunes:duration>0:00:50</itunes:duration>
      <itunes:length>695512</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Hannah Mamuszka, Who is the Customer? - Episode 4]]></title>
      <description><![CDATA[Hannah Mamuszka, CEO of Alva10  tells us how cost-based pricing and the commoditization of diagnostic tests has stifled innovation.  The promise of value-based pricing, though, is still very much alive.  The key, she says,  lies in restructuring the relationship between the diagnostics providers and the payors.]]></description>
      <guid isPermaLink="false">26UZNC7G-2CU40A4</guid>
      <pubDate>Fri, 17 Jan 2020 21:57:57 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/hannah-2.mp3" length="24934195" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Hannah Mamuszka, CEO of Alva10  tells us how cost-based pricing and the commoditization of diagnostic tests has stifled innovation.  The promise of value-based pricing, though, is still very much alive.  The key, she says,  lies in restructuring the  ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Hannah Mamuszka, CEO of Alva10  tells us how cost-based pricing and the commoditization of diagnostic tests has stifled innovation.  The promise of value-based pricing, though, is still very much alive.  The key, she says,  lies in restructuring the relationship between the diagnostics providers and the payors.]]></itunes:summary>
      <itunes:duration>0:29:23</itunes:duration>
      <itunes:length>24934195</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Roger Klein MD, JD, part ii - Preview 3]]></title>
      <description><![CDATA["This is a golden age; we're just scratching the surface."]]></description>
      <guid isPermaLink="false">JKUMW4VV-96YLDI</guid>
      <pubDate>Thu, 16 Jan 2020 22:04:32 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/roger-klein-part-ii-preview-3.mp3" length="384029" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["This is a golden age; we're just scratching the surface."]]></itunes:subtitle>
      <itunes:summary><![CDATA["This is a golden age; we're just scratching the surface."]]></itunes:summary>
      <itunes:duration>0:00:34</itunes:duration>
      <itunes:length>384029</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Roger Klein, MD, JD part ii - Preview 2]]></title>
      <description><![CDATA["It's actually a good thing from an economics standpoint..."  Dr. Roger Klein on whether falling prices can help spur innovation]]></description>
      <guid isPermaLink="false">AAXVOM04-L6P3NMI</guid>
      <pubDate>Thu, 16 Jan 2020 19:30:08 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Roger-Klein-part-ii-promo-2.mp3" length="546294" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["It's actually a good thing from an economics standpoint..."  Dr. Roger Klein on whether falling prices can help spur innovation]]></itunes:subtitle>
      <itunes:summary><![CDATA["It's actually a good thing from an economics standpoint..."  Dr. Roger Klein on whether falling prices can help spur innovation]]></itunes:summary>
      <itunes:duration>0:00:48</itunes:duration>
      <itunes:length>546294</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Roger Klein, MD, JD part ii - Preview 1]]></title>
      <description><![CDATA[“I’m going to have to present a counter view.  I think no.  These types of tests are going to be commoditized as more providers come into the space.”  Roger Klein, MD, JD on if diagnostics providers are going to be able to capture value in the liquid biopsy market]]></description>
      <guid isPermaLink="false">9NLYAHBX-NS714I</guid>
      <pubDate>Thu, 16 Jan 2020 19:20:55 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Roger-Klein-part-ii-preview1.mp3" length="173363" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[“I’m going to have to present a counter view.  I think no.  These types of tests are going to be commoditized as more providers come into the space.”  Roger Klein, MD, JD on if diagnostics providers are going to be able to capture value in the liquid ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[“I’m going to have to present a counter view.  I think no.  These types of tests are going to be commoditized as more providers come into the space.”  Roger Klein, MD, JD on if diagnostics providers are going to be able to capture value in the liquid biopsy market]]></itunes:summary>
      <itunes:duration>0:00:15</itunes:duration>
      <itunes:length>173363</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Roger Klein, MD, JD, part ii, Are we Spiraling to the Bottom? - Episode 3]]></title>
      <description><![CDATA[Are we spiraling to the bottom?  Is there any hope for value-based pricing in diagnostics?

Roger D. Klein MD, JD, FCAP is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology (AMP) Solid Tumors Division.  A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes. He is a leading authority on public policies related to the implementation of precision medicine.

]]></description>
      <guid isPermaLink="false">C7Y4H8VH-BNPNWMI</guid>
      <pubDate>Tue, 07 Jan 2020 19:07:57 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Roger-Klein-part-ii-Episode-3.mp3" length="14218195" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Are we spiraling to the bottom?  Is there any hope for value-based pricing in diagnostics?

Roger D. Klein MD, JD, FCAP is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology (AMP) Solid T ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Are we spiraling to the bottom?  Is there any hope for value-based pricing in diagnostics?

Roger D. Klein MD, JD, FCAP is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology (AMP) Solid Tumors Division.  A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes. He is a leading authority on public policies related to the implementation of precision medicine.

]]></itunes:summary>
      <itunes:duration>0:19:31</itunes:duration>
      <itunes:length>14218195</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Roger Klein, MD JD  - preview 1]]></title>
      <description><![CDATA[Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division.  A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes.]]></description>
      <guid isPermaLink="false">G90XT093-FUHAOR</guid>
      <pubDate>Tue, 17 Dec 2019 18:51:54 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/roger-klein-promo1.mp3" length="1122646" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division.  A physician and an attorney, Dr Klein served as an expert and key spokesperso ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division.  A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes.]]></itunes:summary>
      <itunes:duration>0:01:16</itunes:duration>
      <itunes:length>1122646</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Roger Klein, MD JD, How are Molecular Diagnostcs Tests Reimbursed? -  Episode 2]]></title>
      <description><![CDATA[How exactly are molecular diagnostic tests reimbursed?

Is our current coding and reimbursement system up to the task?

How does a new test achieve reimbursement?

Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division.  A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes.
]]></description>
      <guid isPermaLink="false">E6LNPH9M-U8R529</guid>
      <pubDate>Tue, 17 Dec 2019 17:23:14 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Roger-Klein-Episode-2.mp3" length="21646459" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[How exactly are molecular diagnostic tests reimbursed?

Is our current coding and reimbursement system up to the task?

How does a new test achieve reimbursement?

Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate p ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[How exactly are molecular diagnostic tests reimbursed?

Is our current coding and reimbursement system up to the task?

How does a new test achieve reimbursement?

Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division.  A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes.
]]></itunes:summary>
      <itunes:duration>0:26:28</itunes:duration>
      <itunes:length>21646459</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Dr. Jill Hagenkord, Bridging the Gap Between Health Tech and Health Care -  Episode 1]]></title>
      <description><![CDATA[Can we bridge the cultural gap between health tech and health care?  What happens when "fail fast, fail often " and "move quickly and break things" meets patient care?

Dr. Jill Hagenkord, the co-founder of MDisrupt  and previous Chief Medical Officer at Complete Genomics, Invitae, 23 and Me and Color Genomics joins us.]]></description>
      <guid isPermaLink="false">7Z1P1JZN-35QXGVI</guid>
      <pubDate>Mon, 09 Dec 2019 16:15:00 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Episode-1-Jill-Hagenkord.mp3" length="16362801" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Can we bridge the cultural gap between health tech and health care?  What happens when "fail fast, fail often " and "move quickly and break things" meets patient care?

Dr. Jill Hagenkord, the co-founder of MDisrupt  and previous Chief Medical Office ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Can we bridge the cultural gap between health tech and health care?  What happens when "fail fast, fail often " and "move quickly and break things" meets patient care?

Dr. Jill Hagenkord, the co-founder of MDisrupt  and previous Chief Medical Officer at Complete Genomics, Invitae, 23 and Me and Color Genomics joins us.]]></itunes:summary>
      <itunes:duration>0:28:09</itunes:duration>
      <itunes:length>16362801</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Dr. Jill Hagenkord - Preview 3]]></title>
      <description><![CDATA["We're going to have to make it more patient-centric in the very near future."]]></description>
      <guid isPermaLink="false">GYT3OTOZ-9AFW29</guid>
      <pubDate>Thu, 05 Dec 2019 04:55:44 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Jill-Hagenkord-Preview-3.mp3" length="288457" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["We're going to have to make it more patient-centric in the very near future."]]></itunes:subtitle>
      <itunes:summary><![CDATA["We're going to have to make it more patient-centric in the very near future."]]></itunes:summary>
      <itunes:duration>0:00:34</itunes:duration>
      <itunes:length>288457</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Dr. Jill Hagenkord  - Preview 2]]></title>
      <description><![CDATA["Think of the difference we could make in healthcare."]]></description>
      <guid isPermaLink="false">I14VG1VX-86W29</guid>
      <pubDate>Wed, 04 Dec 2019 16:29:17 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Jill-Hagenkord-Preview-2.mp3" length="474572" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA["Think of the difference we could make in healthcare."]]></itunes:subtitle>
      <itunes:summary><![CDATA["Think of the difference we could make in healthcare."]]></itunes:summary>
      <itunes:duration>0:00:56</itunes:duration>
      <itunes:length>474572</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Dr. Jill Hagenkord  - Preview 1]]></title>
      <description><![CDATA[The culture clash between tech and healthcare]]></description>
      <guid isPermaLink="false">EC80MQ8M-RO1OR</guid>
      <pubDate>Wed, 04 Dec 2019 16:27:41 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Jill-Hagenkord-Preview-1.mp3" length="553788" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[The culture clash between tech and healthcare]]></itunes:subtitle>
      <itunes:summary><![CDATA[The culture clash between tech and healthcare]]></itunes:summary>
      <itunes:duration>0:01:06</itunes:duration>
      <itunes:length>553788</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
    <item>
      <title><![CDATA[Welcome - Episode 0]]></title>
      <description><![CDATA[Welcome to the Personalized Diagnostics Podcast.

In the upcoming weeks we are going to be talking to some of the greatest minds and personalities in the diagnostics space – the engine which is driving personalized medicine forward.

Thanks for listening.  
]]></description>
      <guid isPermaLink="false">I1KZKGDR-L1H5MI</guid>
      <pubDate>Wed, 04 Dec 2019 16:22:54 GMT</pubDate>
      <enclosure url="https://cast.rocks/hosting/21156/Welcome.mp3" length="838901" type="audio/mpeg"/>
      <itunes:author></itunes:author>
      <itunes:explicit>clean</itunes:explicit>
      <itunes:subtitle><![CDATA[Welcome to the Personalized Diagnostics Podcast.

In the upcoming weeks we are going to be talking to some of the greatest minds and personalities in the diagnostics space – the engine which is driving personalized medicine forward.

Thanks for liste ...]]></itunes:subtitle>
      <itunes:summary><![CDATA[Welcome to the Personalized Diagnostics Podcast.

In the upcoming weeks we are going to be talking to some of the greatest minds and personalities in the diagnostics space – the engine which is driving personalized medicine forward.

Thanks for listening.  
]]></itunes:summary>
      <itunes:duration>0:01:02</itunes:duration>
      <itunes:length>838901</itunes:length>
      <itunes:keywords></itunes:keywords>
      
    </item>
  </channel>
</rss>